Pricing Log in Create free account

RxSight, Inc. (RXST) vs TriSalus Life Sciences, Inc. (TLSI)

RxSight, Inc. and TriSalus Life Sciences, Inc. are both Medical Devices companies. TriSalus Life Sciences, Inc. is the larger, with a market value of $217.4M against $190.4M — 1.1× the size. TriSalus Life Sciences, Inc. grew revenue faster over the last twelve months: 25.3% against −14.3%. RxSight, Inc. has the higher net margin (−43.8% vs −130.2%) and the lower return on invested capital (−16,845.7% vs 0.00%). Across the 17 metrics below, RxSight, Inc. leads on 11 and TriSalus Life Sciences, Inc. on 6.

Valuation

Metric RXST TLSI Medical Devices median
P/E n/m n/m 24.94
P/S 1.56 4.22 2.66
P/B 0.75 29.02 2.36
Price to free cash flow 10.22 n/m 28.12
EV/EBITDA 0.68 n/m 11.42
EV/Sales (0.37) 3.93 2.76
Earnings yield (27.99%) (39.88%) (12.66%)
Free cash flow yield 9.78% (12.62%) (7.18%)

Profitability

Metric RXST TLSI Medical Devices median
Gross margin 76.13% 85.79% 57.76%
Operating margin (50.44%) (67.68%) (14.84%)
Net margin (43.80%) (130.17%) (14.45%)
Free cash flow margin 15.30% (51.56%) (5.70%)
Return on equity (20.10%) 911.60% (10.56%)
Return on assets (16.44%) (113.09%) (17.26%)
Return on invested capital (16,845.67%) 0.00% (5.22%)

Growth

Metric RXST TLSI Medical Devices median
Revenue growth (TTM) (14.26%) 25.25% 10.41%
EPS growth (last fiscal year) (33.80%) (40.46%) 28.17%
Revenue growth, 5-year CAGR 55.74% — 15.74%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric RXST TLSI Medical Devices median
Debt to equity 0.00 5.05 0.04
Current ratio 4.20 5.35 2.67
Net debt to EBITDA 4.27 (0.50) 0.54

Dividend

Metric RXST TLSI Medical Devices median
Dividend yield — — 1.02%
Payout ratio — — 0.38

Size

Metric RXST TLSI Medical Devices median
Market cap 190.36m 217.36m 221.84m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack